Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

TC BioPharm (Holdings) plc - American Depositary Shares (NQ:TCBP)

0.5000 UNCHANGED
Last Price Updated: 4:00 PM EDT, Mar 21, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about TC BioPharm (Holdings) plc - American Depositary Shares

< Previous 1 2 Next >
BioMedNewsBreaks — TC BioPharm Holdings PLC (NASDAQ: TCBP) to Be Delisted, Will Move to OTC Markets
Via Investor Brand Network
InvestorNewsBreaks – TC BioPharm Holdings PLC (NASDAQ: TCBP) Restructures Operations to Enhance Efficiency and Reduce Costs
Via Investor Brand Network
BioMedNewsBreaks — TC BioPharm Holdings PLC (NASDAQ: TCBP) Signs Letter of Intent to Acquire Ophthalmic Pharma Company
Via Investor Brand Network
InvestorNewsBreaks – TC BioPharm Holdings PLC (NASDAQ: TCBP) CEO to Speak at European Life Sciences CEO Forum
Via Investor Brand Network
Topics Artificial Intelligence
Exposures Artificial Intelligence
InvestorNewsBreaks – TC BioPharm Holdings PLC (NASDAQ: TCBP) Completes Dosing in Phase 2B AML Trial, Reports Positive Early Data
Via Investor Brand Network
InvestorNewsBreaks – TC BioPharm Holdings PLC (NASDAQ: TCBP) Advances ACHIEVE Trial With Completion of First Cohort B Dosing
Via Investor Brand Network
InvestorNewsBreaks – TC BioPharm Holdings PLC (NASDAQ: TCBP) Announces ADS Ratio Change Effective Feb. 10
Via Investor Brand Network
InvestorNewsBreaks – TC BioPharm Holdings PLC (NASDAQ: TCBP) Advances Preclinical Studies for Bird Flu Treatment with TCB008
Via Investor Brand Network
BioMedNewsBreaks — TC BioPharm Holdings PLC (NASDAQ: TCBP) to Present at Sequire Investor Summit 2025
Via Investor Brand Network
BioMedNewsBreaks — TC BioPharm Holdings PLC (NASDAQ: TCBP) Confirms Continued Nasdaq Trading Under TCBP
Via Investor Brand Network
InvestorNewsBreaks – TC BioPharm Holdings PLC (NASDAQ: TCBP) Shareholders Approve 25% Stock Dividend
Via Investor Brand Network
BioMedNewsBreaks — TC BioPharm Holdings PLC (NASDAQ: TCBP) Reports Positive Safety Data in ACHIEVE Phase 2b Trial for AML and MDS/AML
Via Investor Brand Network
BioMedNewsBreaks — TC BioPharm Holdings PLC (NASDAQ: TCBP) Announces Special Dividend for Shareholders Amid Ongoing Support
Via Investor Brand Network
Topics Regulatory Compliance
Exposures Legal Regulatory
BioMedNewsBreaks — TC BioPharm Holdings PLC (NASDAQ: TCBP) and CareDx Collaborate to Enhance TCB008 Cell Therapy Development for AML
Via Investor Brand Network
InvestorNewsBreaks – TC BioPharm Holdings PLC (NASDAQ: TCBP) Issues Update on ACHIEVE Clinical Trial
Via Investor Brand Network
InvestorNewsBreaks – TC BioPharm Holdings PLC (NASDAQ: TCBP) Receives $250,000 Grant to Enhance TCB008 Manufacturing Efficiency
Via Investor Brand Network
InvestorNewsBreaks – TC BioPharm Holdings PLC (NASDAQ: TCBP) Updates Shareholders on Major Milestones, Expands Clinical Trial Sites and Secures $8M Funding in 2024
Via Investor Brand Network
BioMedNewsBreaks — TC BioPharm Holdings PLC (NASDAQ: TCBP) Announces Collaboration for Monkeypox Treatment Development
Via Investor Brand Network
BioMedNewsBreaks — TC BioPharm Holdings PLC (NASDAQ: TCBP), Carnegie Mellon University Partner to Potentially Revolutionize Donor Selection, Matching Processes with AI
Via Investor Brand Network
Topics Artificial Intelligence
Exposures Artificial Intelligence
BioMedNewsBreaks — TC BioPharm Holdings PLC (NASDAQ: TCBP) Announces Newly Opened London-Based ACHIEVE UK Trial Site Amid ‘Very Positive’ Study Progression
Via Investor Brand Network
BioMedNewsBreaks — TC Biopharm (Holdings) PLC (NASDAQ: TCBP) Featured at Next Month’s NYC ThinkEquity Conference
Via Investor Brand Network
BioMedNewsBreaks — TC Biopharm (Holdings) PLC (NASDAQ: TCBP) Completes ACHIEVE Trial Full-Dose Regimen for First Patient
Via Investor Brand Network
InvestorNewsBreaks – TC BioPharm Holdings PLC (NASDAQ: TCBP) Marks Milestone as First Patient Completes Full Dose in ACHIEVE Trial with No Adverse Events
Via Investor Brand Network
BioMedNewsBreaks — TC Biopharm (Holdings) PLC (NASDAQ: TCBP) Plans Preclinical Studies for Treatment of Monkey Pox
Via Investor Brand Network
BioMedNewsBreaks — TC BioPharm Holdings PLC (NASDAQ: TCBP) CEO to Present at the H.C. Wainwright 26th Annual Global Investment Conference
Via Investor Brand Network
BioMedNewsBreaks — TC Biopharm (Holdings) PLC (NASDAQ: TCBP) Doses Five New Patients in UK ACHIEVE Phase 2b Trial
Via Investor Brand Network
TC BioPharm CEO, Bryan Kobel, is Featured on The Stock Day Podcast
Phoenix, Arizona--(Newsfile Corp. - July 6, 2023) - The Stock Day Podcast welcomed TC BioPharm Holdings, PLC. (NASDAQ: TCBP) ("the... 
Via Newsfile
Exposures Product Safety
Initiatives For Development of Gamma Delta T Cell Therapies Driven by Large Number of Clinical Trials
EQNX::TICKER_START (NASDAQ:TCBP),(NASDAQ:CRDF),(NASDAQ:CYAD),(NASDAQ:RIGL),(NASDAQ:AZN) EQNX::TICKER_END 
Via FinancialNewsMedia
Exposures COVID-19 Product Safety
Why the Relapsed/Refractory Acute Myeloid Leukemia Market is Expected to Witness Revolutionary Developments
EQNX::TICKER_START (NASDAQ:TCBP),(NYSE:CVM),(NASDAQ:INVO),(NASDAQ:SNY),(NYSE:PFE) EQNX::TICKER_END 
Via FinancialNewsMedia
Exposures Product Safety
TC BioPharm Announces Strategic Collaboration to Advance Gamma Delta T Cells in Oncology
EQNX::TICKER_START (NASDAQ:TCBP) EQNX::TICKER_END 
Via FinancialNewsMedia
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.